De Abhishek, Das Sudip, Dhoot Dhiraj, Sarda Aarti
Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India.
Medical Services, Glenmark Pharmaceuticals Ltd, Mumbai, Maharashtra, India.
Indian J Dermatol. 2019 May-Jun;64(3):239-241. doi: 10.4103/ijd.IJD_548_18.
Psoriasis is a chronic immune-mediated inflammatory condition, affecting 2-3% of the population. In recent years, advent of biologics, including secukinumab, have been a major advancement in the management of difficult-to-treat plaque psoriasis. However, high cost of biologics is often a deterrent, especially for Indian socioeconomic condition. Apremilast is an oral phosphodiesterase 4 inhibitor that is safe for use along with many other systemic therapies of psoriasis, including biologics. We report two cases of psoriasis on secukinumab therapy for long duration with good response to therapy. Later, addition of apremilast, allowed halving the dose of secukinumab with maintenance of improvement.
银屑病是一种慢性免疫介导的炎症性疾病，影响着2%-3%的人口。近年来，包括司库奇尤单抗在内的生物制剂的出现，是治疗难治性斑块状银屑病的一项重大进展。然而，生物制剂的高成本往往是一个阻碍，特别是对于印度的社会经济状况而言。阿普米拉斯是一种口服磷酸二酯酶4抑制剂，与许多其他银屑病全身治疗方法（包括生物制剂）联合使用是安全的。我们报告了两例长期使用司库奇尤单抗治疗且对治疗反应良好的银屑病病例。后来，加用阿普米拉斯后，司库奇尤单抗剂量减半且病情维持改善。
